France has entered a new, more disciplined era in the governance of diagnostic innovation—an era in which public funding is tied directly to evidence, real-world performance, and measurable system-level value, …

How HRGs, tariffs, OPCS coding and clinical data science quietly determine how UK hospitals are funded and why this machinery shapes every diagnosis, procedure and financial decision across the NHS. …

Executive Summary: Conditional Reimbursement and Evidence-Linked Market Access Across Europe Europe’s healthcare systems are entering a new phase where biotech, pharmaceutical, MedTech, and digital innovations are funded not simply for …

How Germany’s Reimbursement System Evaluates Evidence and Cost Why the G-BA Matters In Germany, reimbursement decisions begin and end with the Gemeinsamer Bundesausschuss (G-BA) — the Federal Joint Committee responsible …

The Promise and the Paradox The UK Government’s 10-Year Health Plan for England (2025–2035) presents itself as a blueprint for a modernised NHS—one that is digitally enabled, outcomes-measured, genomically informed, …

Beginning in 2026, PMCF stops being a compliance afterthought and becomes the single biggest determinant of CE-mark renewal.Notified Bodies (NBs) are raising scientific standards, CORE-MD has formalised acceptable methodologies, and …